New drug SIBP-A13 enters human testing for hard-to-treat cancers

NCT ID NCT06298058

Recruiting now Disease control Sponsor: Shanghai Institute Of Biological Products Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called SIBP-A13 in 144 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow their growth. Participants will receive the drug by injection and be closely monitored for side effects and how the drug moves through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer head and neck squamous cell carcinoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Shanghai Pulmonary Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.